Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

被引:4
|
作者
Zhai, Xiaoqian [1 ]
Wu, Qiang [1 ]
Pu, Dan [1 ]
Yin, Liyuan [1 ]
Wang, Weiya [2 ]
Zhu, Daxing [1 ]
Xu, Feng [1 ]
机构
[1] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Pathol Dept, Chengdu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ALK fusion; ALK-GCA and EML4-ALK; stage IIIB-N2 NSCLC; alectinib; adjuvant targeted therapy; POSTOPERATIVE RADIOTHERAPY; CANCER; CRIZOTINIB; CHEMOTHERAPY; SURVIVAL;
D O I
10.3389/fonc.2021.782682
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses to different-generation ALK-TKIs. In this case report, we identified a novel non-reciprocal ALK fusion: ALK-grancalcin (GCA) (A19: intragenic) and EML4-ALK (E20: A20) by next-generation sequencing (NGS) in a male lung adenocarcinoma patient who was staged as IIIB-N2 after surgery. After a multidisciplinary discussion, the patient received alectinib adjuvant targeted therapy and postoperative radiotherapy (PORT). He is currently in good condition, and disease-free survival (DFS) has been 20 months so far, which has been longer than the median survival time of IIIB NSCLC patients. Our study extended the spectrum of ALK fusion partners in ALK + NSCLC, and we reported a new ALK fusion: ALK-GCA and EML4-ALK and its sensitivity to alectinib firstly in lung cancer. It is vital for clinicians to detect fusion mutations of patients and report timely the newfound fusions and their response to guide treatment.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Two novel EML4-ALK fusion variants involving EML4 exon 17 identified in lung cancer
    Li, Hai-Rong
    Sanders, Heather R.
    Sferruzza, Anthony D.
    Novic, Connie
    Meloni-Ehrig, Aurelia M.
    Albitar, Maher
    [J]. CANCER RESEARCH, 2010, 70
  • [32] Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report
    Li, Yumei
    Lu, Shijin
    Yao, Ping
    Huang, Wenchuang
    Huang, Yong
    Zhou, Ying
    Yuan, Ying
    Cheng, Shaochen
    Wu, Fasheng
    [J]. MEDICINE, 2024, 103 (03) : E36992
  • [33] Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: A case report
    Ohba, Taro
    Sugio, Kenji
    Kometani, Takuro
    Yamaguchi, Masafumi
    Hamatake, Motoharu
    Nosaki, Kaname
    Takeoka, Hiroaki
    Kitajima, Hiromoto
    Hirai, Fumihiko
    Seto, Takashi
    Taguchi, Kenichi
    Nishiyama, Kenichi
    Shida, Yoshitaka
    Ichinose, Yukito
    [J]. LUNG CANCER, 2011, 73 (03) : 375 - 378
  • [34] A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene
    Chen, Xiaoxia
    Zhang, Jie
    Hu, Qiong
    Li, Xuefei
    Zhou, Caicun
    [J]. LUNG CANCER, 2013, 81 (02) : 308 - 310
  • [35] A CASE OF LUNG ADENOCARCINOMA RESISTANT TO CRIZOTINIB HARBORING KRAS MUTATION AND EML4-ALK FUSION GENE
    Anai, Satoshi
    Suzuki, Kunihiro
    Sueishi, Katsuo
    Harada, Taishi
    Toyokawa, Gouji
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Takayama, Koichi
    Ichinose, Yukito
    Nakanishi, Yoichi
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [36] RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report
    Yan, Huan
    Zeng, Liang
    Zhang, Yongchang
    [J]. HELIYON, 2024, 10 (09)
  • [37] SEQUENCE COMPLEXITY OF EML4-ALK FUSION VARIANTS IDENTIFIED IN NON-SMALL CELL LUNG CANCER
    Zhang, Xu-Chao
    Wu, Yi-Long
    Tian, Hong-Xia
    Yang, Jin-Ji
    Yang, Xue-Ning
    Zhou, Qing
    Su, Jian
    Chen, Zhi-Hong
    An, She-Juan
    Zhi, Xie
    Guo, Wei-Bang
    Chen, Shi-Liang
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1009 - S1010
  • [38] Dual Drive Coexistence of EML4-ALK Fusion and TPM3-ROS1 Fusion Lung Adenocarcinoma: A Case Report
    Zhu, Y.
    Xu, C.
    Wang, W.
    Zhuang, W.
    Chen, G.
    Du, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1033 - S1033
  • [39] A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB
    Menefee, Michael E.
    D'Amico, Thomas A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1315 - S1316
  • [40] Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report
    Tang, Quanying
    Li, Tong
    Ren, Fan
    Li, Xuanguang
    Cao, WeiBo
    Yu, Haochuan
    Mao, Fuling
    Cao, Cancan
    Zu, Lingling
    Xu, Song
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (02):